Skip to main content

Recent News

Hypertension not associated with High NSAID Doses in AxSpA At the SPARTAN meeting, Dr.Meade-Aguilar reported that amongst axSpA patients receiving NSAIDs, there was no diff in the risk for hypertension when comparing those on high vs. low dose NSAIDs. https://t.co/UsRfobVHO7 https://t.co/fGj5yO53Yk
Dr. John Cush @RheumNow (  View Tweet)

ACR Website to Support Primary Care Practitioners

ACR

The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for primary care physicians (PCP) and advanced practice providers (APP) offering them expanded support and guidance to identify rheumatic diseases in their patients.

Read Article
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/vEQUZGAuJe
Dr. John Cush @RheumNow (  View Tweet)
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/xPXUd9vHyE https://t.co/uESOGYhAdw
Dr. John Cush @RheumNow (  View Tweet)
Most leaders value loyalty. Great leaders put a higher premium on integrity. Loyalty is allegiance to power. You're expected to show deference and follow orders. Integrity is allegiance to principles. You're expected to challenge orders that violate your mission or values.

Adam Grant @AdamMGrant (  View Tweet)

No Great Options for Treating VEXAS For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed. https://t.co/tjCX1STnnD https://t.co/Bn40Nfxy9Y
Dr. John Cush @RheumNow (  View Tweet)
The Window of Opportunity (5.24.2024) Dr. Jack Cush reviews the journal reports and news from the past week on https://t.co/V10S4oVFsv. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis? https://t.co/zSjb2tKPWY

Dr. John Cush @RheumNow (  View Tweet)

Hypertension not associated with High NSAID Doses in AxSpA

Medscape

At the recent SPARTAN annual meeting in Cleveland, Dr. Jose Meade-Aguilar reported that amongst axial spondyloarthritis patients receiving nonsteroidal anti-inflammatory drugs, there was no difference in the risk for hypertension when comparing those on high vs. low dose NSAIDs.

Read Article
Preliminary results of ph IIB ORIGIN trial of placebo vs Atacicept (binds BAFF & APRIL)in 166 pts w/ IgA Nephropathy (Berger’s Dz) Gd-IgA1, hematuria, and UPCR (vs PBO) in the blinded 1st 36 weeks of the trial. https://t.co/tPhCrSaSTC https://t.co/6HqGFtb1IE
Dr. John Cush @RheumNow (  View Tweet)
NHANES study of 2500 #RA pts, found a significant correlation between an inflammatory diet (meas by DII score) and inflammatory indices like systemic immune-inflamm Index (SII) & neutrophil-lymphocyte ratio (NLR) https://t.co/sWXZRrG6hV https://t.co/9IcLDF1Jlo
Dr. John Cush @RheumNow (  View Tweet)
Gangsin: 갱신 Korean: refresh, renew, updated Over the last 20+ years, I have listened to patients confide their personal stories. Some remained paralyzed in their current state of distress, --I was one of them https://t.co/Tr9w1XpWL0 https://t.co/E3kLnvfqOb
Dr. John Cush @RheumNow (  View Tweet)
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort https://t.co/IB0cOAFnwl https://t.co/zpwm3JRKU4
Nelly ZIADE 🍀 @Nellziade (  View Tweet)
The ability to predict hip fractures just went to a new level https://t.co/k9cAPIJigd A proteomic risk score was found to be strongly predictive of incident hip fractures in multiple independent populations @NatureAging https://t.co/WZemPZqsev
Eric Topol @EricTopol (  View Tweet)
Available online, open access: A review of CAR-T call therapy in rheumatic disease by @RyuOhno06 See below diagram of CAR-T therapy mechanism in cancer. https://t.co/WALWulEDkW https://t.co/k1FD0zHtWu
Seminars in Arthritis and Rheumatism @seminarthrheum (  View Tweet)
Congratulations to CRA member Dr. Andrew Chow, recipient of the Ontario Rheumatology Association's Rheumatologist of the Year Award! 🏆👏 https://t.co/2fB77VOBhv
CRA SCR @CRASCRRheum (  View Tweet)
Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development https://t.co/DFdQy1Rn3D

Peter Nash @drpnash (  View Tweet)

Congratulations to CRA member Dr. Lauren King, recipient of the Ontario Rheumatology Association's Early Career Rheumatology Award! 🏆👏 https://t.co/iM5MxzVaTg
CRA SCR @CRASCRRheum (  View Tweet)
Biomarkers Predictive of a Deucravacitinib Response in PsA A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in PsA suggests specific biologic effects identified by biomarkers may predict clinical responses. https://t.co/zsZl7JQydn https://t.co/4mGBYB4qU4
Dr. John Cush @RheumNow (  View Tweet)
Lupus Research Alliance Grants for Lupus Innovation The LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA). https://t.co/v3S8u8aVvr https://t.co/Ve7OcIJT03
Dr. John Cush @RheumNow (  View Tweet)
Save the date! We are covering #EULAR24 ! Will we see you there? https://t.co/aMGYnPxlXh
Dr. John Cush @RheumNow (  View Tweet)